{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:17:22Z","timestamp":1794014242375,"version":"4.8.0"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["AI155510"],"award-info":[{"award-number":["AI155510"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Global Alliance for TB Drug Development","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Milstein Program in Chemical Biology and Translational Medicine","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-055896,INV-055894"],"award-info":[{"award-number":["INV-055896,INV-055894"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-040484,INV-005757"],"award-info":[{"award-number":["INV-040484,INV-005757"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-040482"],"award-info":[{"award-number":["INV-040482"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-047552,INV-07007,INV-083642"],"award-info":[{"award-number":["INV-047552,INV-07007,INV-083642"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-056399,INV-005585"],"award-info":[{"award-number":["INV-056399,INV-005585"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-070003"],"award-info":[{"award-number":["INV-070003"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-044686"],"award-info":[{"award-number":["INV-044686"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-040487"],"award-info":[{"award-number":["INV-040487"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Despite the approval of two first-in-class anti-tuberculars over the past two decades, the global burden of tuberculosis (TB) remains unacceptably high, in part due to the emergence and spread of drug-resistant strains of\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    (\n                    <jats:italic>Mtb<\/jats:italic>\n                    ). This review summarizes advances and ongoing challenges in anti-TB drug discovery, focusing on identifying and validating novel targets. Highlighted is a framework developed by the TB Drug Accelerator (TBDA) consortium for target validation in\n                    <jats:italic>Mtb<\/jats:italic>\n                    . Two computational platforms, DAIKON and PARSNIP, allow the systematic evaluation of targets across multiple dimensions, including chemical validation, genetic essentiality, vulnerability, and the feasibility to identify drug-like molecules for a target of interest. Case studies of Pks13 and NadE illustrate how these parameters guide target prioritization and risk assessment. By integrating these metrics, the framework enables dynamic, transparent target ranking, supporting development of both pan-TB and treatment-shortening regimens. This paradigm is adaptable to other bacterial pathogens and is designed to improve evidence-based decision-making in antibacterial drug discovery.\n                  <\/jats:p>","DOI":"10.1038\/s44321-026-00415-7","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T15:51:07Z","timestamp":1775577067000},"page":"1495-1507","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4445-7219","authenticated-orcid":false,"given":"Dirk","family":"Schnappinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1250-0208","authenticated-orcid":false,"given":"Steven J","family":"Berthel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4333-206X","authenticated-orcid":false,"given":"Helena I M","family":"Boshoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna V","family":"Krieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paridhi","family":"Sukheja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2057-8822","authenticated-orcid":false,"given":"Saswati","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1179-0453","authenticated-orcid":false,"given":"Siddhant","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5315-1203","authenticated-orcid":false,"given":"Xuelin","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sari","family":"Rasheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A T","family":"Cleghorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Ghorpade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk A","family":"Lamprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Fotouhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1042-5665","authenticated-orcid":false,"given":"Rolf","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7744-8896","authenticated-orcid":false,"given":"Carl","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Parish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9374-7024","authenticated-orcid":false,"given":"Peter","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Case W","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9310-951X","authenticated-orcid":false,"given":"Jeremy M","family":"Rock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C","family":"Sacchettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4824-9115","authenticated-orcid":false,"given":"Valerie","family":"Mizrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"415_CR1","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.chembiol.2012.05.020","volume":"19","author":"GL Abrahams","year":"2012","unstructured":"Abrahams GL, Kumar A, Savvi S, Hung AW, Wen S, Abell C, Barry 3rdCE, Sherman DR, Boshoff HI, Mizrahi V (2012) Pathway-selective sensitization of Mycobacterium tuberculosis for target-based whole-cell screening. Chem Biol 19:844\u2013854","journal-title":"Chem Biol"},{"key":"415_CR2","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1021\/bi5000564","volume":"53","author":"KJ Aldred","year":"2014","unstructured":"Aldred KJ, Kerns RJ, Osheroff N (2014) Mechanism of quinolone action and resistance. Biochemistry 53:1565\u20131574","journal-title":"Biochemistry"},{"key":"415_CR3","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s41591-021-01442-2","volume":"27","author":"BB Aldridge","year":"2021","unstructured":"Aldridge BB, Barros-Aguirre D, Barry 3rdCE, Bates RH, Berthel SJ, Boshoff HI, Chibale K, Chu XJ, Cooper CB, Dartois V et al (2021) The Tuberculosis Drug Accelerator at year 10: what have we learned? Nat Med 27:1333\u20131337","journal-title":"Nat Med"},{"key":"415_CR4","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.bbrc.2017.09.087","volume":"493","author":"C Anand","year":"2017","unstructured":"Anand C, Garg R, Ghosh S, Nagaraja V (2017) A Sir2 family protein Rv1151c deacetylates HU to alter its DNA binding mode in Mycobacterium tuberculosis. Biochem Biophys Res Commun 493:1204\u20131209","journal-title":"Biochem Biophys Res Commun"},{"key":"415_CR5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1126\/science.1106753","volume":"307","author":"K Andries","year":"2005","unstructured":"Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E et al (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223\u2013227","journal-title":"Science"},{"key":"415_CR6","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1021\/acsinfecdis.4c00499","volume":"10","author":"P Ashwath","year":"2024","unstructured":"Ashwath P, Osiecki P, Weiner D, Via LE, Sarathy JP (2024) Role of DNA double-strand break formation in gyrase inhibitor-mediated killing of nonreplicating persistent Mycobacterium tuberculosis in caseum. ACS Infect Dis 10:3631\u20133639","journal-title":"ACS Infect Dis"},{"key":"415_CR7","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1093\/jac\/dkac070","volume":"77","author":"A Bateson","year":"2022","unstructured":"Bateson A, Ortiz Canseco J, McHugh TD, Witney AA, Feuerriegel S, Merker M, Kohl TA, Utpatel C, Niemann S, Andres S et al (2022) Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid. J Antimicrob Chemother 77:1685\u20131693","journal-title":"J Antimicrob Chemother"},{"key":"415_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12956-2","volume":"10","author":"T Beites","year":"2019","unstructured":"Beites T, O\u2019Brien K, Tiwari D, Engelhart CA, Walters S, Andrews J, Yang HJ, Sutphen ML, Weiner DM, Dayao EK et al (2019) Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development. Nat Commun 10:4970","journal-title":"Nat Commun"},{"key":"415_CR9","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.drudis.2017.04.012","volume":"22","author":"RP Bhusal","year":"2017","unstructured":"Bhusal RP, Bashiri G, Kwai BXC, Sperry J, Leung IKH (2017) Targeting isocitrate lyase for the treatment of latent tuberculosis. Drug Discov Today 22:1008\u20131016","journal-title":"Drug Discov Today"},{"key":"415_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41426-018-0112-3","volume":"7","author":"J Bi","year":"2018","unstructured":"Bi J, Gou Z, Zhou F, Chen Y, Gan J, Liu J, Wang H, Zhang X (2018) Acetylation of lysine 182 inhibits the ability of Mycobacterium tuberculosis DosR to bind DNA and regulate gene expression during hypoxia. Emerg Microbes Infect 7:108","journal-title":"Emerg Microbes Infect"},{"key":"415_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/srep44826","volume":"7","author":"J Bi","year":"2017","unstructured":"Bi J, Wang Y, Yu H, Qian X, Wang H, Liu J, Zhang X (2017) Modulation of central carbon metabolism by acetylation of isocitrate lyase in Mycobacterium tuberculosis. Sci Rep 7:44826","journal-title":"Sci Rep"},{"key":"415_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64662-x","volume":"16","author":"AN Bond","year":"2025","unstructured":"Bond AN, Orzechowski M, Zhang S, Ben-Zion I, Lemmer A, Garry N, Lee K, Chen M, Delano K, Gath E et al (2025) Reference-based chemical-genetic interaction profiling to elucidate small molecule mechanism of action in Mycobacterium tuberculosis. Nat Commun 16:9673","journal-title":"Nat Commun"},{"key":"415_CR13","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1021\/ci5006004","volume":"55","author":"A Borrel","year":"2015","unstructured":"Borrel A, Regad L, Xhaard H, Petitjean M, Camproux AC (2015) PockDrug: a model for predicting pocket druggability that overcomes pocket estimation uncertainties. J Chem Inf Model 55:882\u2013895","journal-title":"J Chem Inf Model"},{"key":"415_CR14","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1016\/j.cell.2021.06.033","volume":"184","author":"B Bosch","year":"2021","unstructured":"Bosch B, DeJesus MA, Poulton NC, Zhang W, Engelhart CA, Zaveri A, Lavalette S, Ruecker N, Trujillo C, Wallach JB et al (2021) Genome-wide gene expression tuning reveals diverse vulnerabilities of M. tuberculosis. Cell 184:4579\u20134592.e4524","journal-title":"Cell"},{"key":"415_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/nyas.15139","volume":"1535","author":"B Bosch","year":"2024","unstructured":"Bosch B, DeJesus MA, Schnappinger D, Rock JM (2024) Weak links: advancing target-based drug discovery by identifying the most vulnerable targets. Ann N Y Acad Sci 1535:10\u201319","journal-title":"Ann N Y Acad Sci"},{"key":"415_CR16","doi-asserted-by":"publisher","first-page":"19329","DOI":"10.1074\/jbc.M800694200","volume":"283","author":"HI Boshoff","year":"2008","unstructured":"Boshoff HI, Xu X, Tahlan K, Dowd CS, Pethe K, Camacho LR, Park TH, Yun CS, Schnappinger D, Ehrt S et al (2008) Biosynthesis and recycling of nicotinamide cofactors in Mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli. J Biol Chem 283:19329\u201319341","journal-title":"J Biol Chem"},{"key":"415_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14731","volume":"8","author":"L Botella","year":"2017","unstructured":"Botella L, Vaubourgeix J, Livny J, Schnappinger D (2017) Depleting Mycobacterium tuberculosis of the transcription termination factor Rho causes pervasive transcription and rapid death. Nat Commun 8:14731","journal-title":"Nat Commun"},{"key":"415_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01294-22","volume":"67","author":"KL Brown","year":"2023","unstructured":"Brown KL, Wilburn KM, Montague CR, Grigg JC, Sanz O, Perez-Herran E, Barros D, Ballell L, VanderVen BC, Eltis LD (2023) Cyclic AMP-mediated inhibition of cholesterol catabolism in Mycobacterium tuberculosis by the novel drug candidate GSK2556286. Antimicrob Agents Chemother 67:e0129422","journal-title":"Antimicrob Agents Chemother"},{"key":"415_CR19","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1021\/bi900172q","volume":"48","author":"RL Burton","year":"2009","unstructured":"Burton RL, Chen S, Xu XL, Grant GA (2009) Role of the anion-binding site in catalysis and regulation of Mycobacterium tuberculosis D-3-phosphoglycerate dehydrogenase. Biochemistry 48:4808\u20134815","journal-title":"Biochemistry"},{"key":"415_CR20","doi-asserted-by":"publisher","first-page":"e1006939","DOI":"10.1371\/journal.ppat.1006939","volume":"14","author":"AF Carey","year":"2018","unstructured":"Carey AF, Rock JM, Krieger IV, Chase MR, Fernandez-Suarez M, Gagneux S, Sacchettini JC, Ioerger TR, Fortune SM (2018) TnSeq of Mycobacterium tuberculosis clinical isolates reveals strain-specific antibiotic liabilities. PLoS Pathog 14:e1006939","journal-title":"PLoS Pathog"},{"key":"415_CR21","doi-asserted-by":"publisher","first-page":"e1000645","DOI":"10.1371\/journal.ppat.1000645","volume":"5","author":"T Christophe","year":"2009","unstructured":"Christophe T, Jackson M, Jeon HK, Fenistein D, Contreras-Dominguez M, Kim J, Genovesio A, Carralot JP, Ewann F, Kim EH et al (2009) High content screening identifies decaprenyl-phosphoribose 2\u2019 epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog 5:e1000645","journal-title":"PLoS Pathog"},{"key":"415_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13845-4","volume":"11","author":"W Chuenchor","year":"2020","unstructured":"Chuenchor W, Doukov TI, Chang KT, Resto M, Yun CS, Gerratana B (2020) Different ways to transport ammonia in human and Mycobacterium tuberculosis NAD(+) synthetases. Nat Commun 11: 16","journal-title":"Nat Commun"},{"key":"415_CR23","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41579-022-00721-0","volume":"20","author":"ES Chung","year":"2022","unstructured":"Chung ES, Johnson WC, Aldridge BB (2022) Types and functions of heterogeneity in mycobacteria. Nat Rev Microbiol 20:529\u2013541","journal-title":"Nat Rev Microbiol"},{"key":"415_CR24","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","volume":"382","author":"F Conradie","year":"2020","unstructured":"Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, Mendel CM, Egizi E, Moreira J, Timm J et al (2020) Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med 382:893\u2013902","journal-title":"N Engl J Med"},{"key":"415_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/joim.13378","volume":"291","author":"JR Covvey","year":"2022","unstructured":"Covvey JR, Guarascio AJ (2022) Clinical use of lefamulin: a first-in-class semisynthetic pleuromutilin antibiotic. J Intern Med 291:51\u201363","journal-title":"J Intern Med"},{"key":"415_CR26","doi-asserted-by":"publisher","first-page":"eabn7943","DOI":"10.1126\/sciadv.abn7943","volume":"8","author":"FB d\u2019Andrea","year":"2022","unstructured":"d\u2019Andrea FB, Poulton NC, Froom R, Tam K, Campbell EA, Rock JM (2022) The essential M. tuberculosis Clp protease is functionally asymmetric in vivo. Sci Adv 8:eabn7943","journal-title":"Sci Adv"},{"key":"415_CR27","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1038\/s41591-025-03742-3","volume":"31","author":"VA Dartois","year":"2025","unstructured":"Dartois VA, Mizrahi V, Savic RM, Silverman JA, Hermann D, Barry 3rdCE (2025) Strategies for shortening tuberculosis therapy. Nat Med 31:1765\u20131775","journal-title":"Nat Med"},{"key":"415_CR28","doi-asserted-by":"publisher","first-page":"e02133","DOI":"10.1128\/mBio.02133-16","volume":"8","author":"MA DeJesus","year":"2017","unstructured":"DeJesus MA, Gerrick ER, Xu W, Park SW, Long JE, Boutte CC, Rubin EJ, Schnappinger D, Ehrt S, Fortune SM et al (2017) Comprehensive essentiality analysis of the Mycobacterium tuberculosis genome via saturating transposon mutagenesis. MBio 8:e02133\u201316","journal-title":"MBio"},{"key":"415_CR29","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/s41591-024-02829-7","volume":"30","author":"AH Diacon","year":"2024","unstructured":"Diacon AH, Barry 3rdCE, Carlton A, Chen RY, Davies M, de Jager V, Fletcher K, Koh G, Kontsevaya I, Heyckendorf J et al (2024) A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nat Med 30:896\u2013904","journal-title":"Nat Med"},{"key":"415_CR30","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1021\/acsinfecdis.8b00256","volume":"5","author":"J Early","year":"2019","unstructured":"Early J, Ollinger J, Darby C, Alling T, Mullen S, Casey A, Gold B, Ochoada J, Wiernicki T, Masquelin T et al (2019) Identification of compounds with pH-dependent bactericidal activity against Mycobacterium tuberculosis. ACS Infect Dis 5:272\u2013280","journal-title":"ACS Infect Dis"},{"key":"415_CR31","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1021\/acsinfecdis.6b00150","volume":"2","author":"JC Evans","year":"2016","unstructured":"Evans JC, Trujillo C, Wang Z, Eoh H, Ehrt S, Schnappinger D, Boshoff HI, Rhee KY, Barry 3rdCE, Mizrahi V (2016) Validation of CoaBC as a bactericidal target in the coenzyme a pathway of Mycobacterium tuberculosis. ACS Infect Dis 2:958\u2013968","journal-title":"ACS Infect Dis"},{"key":"415_CR32","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41579-024-01025-1","volume":"22","author":"M Farhat","year":"2024","unstructured":"Farhat M, Cox H, Ghanem M, Denkinger CM, Rodrigues C, Abd El Aziz MS, Enkh-Amgalan H, Vambe D, Ugarte-Gil C, Furin J et al (2024) Drug-resistant tuberculosis: a persistent global health concern. Nat Rev Microbiol 22:617\u2013635","journal-title":"Nat Rev Microbiol"},{"key":"415_CR33","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.chembiol.2014.10.011","volume":"21","author":"S Gavalda","year":"2014","unstructured":"Gavalda S, Bardou F, Laval F, Bon C, Malaga W, Chalut C, Guilhot C, Mourey L, Daffe M, Quemard A (2014) The polyketide synthase Pks13 catalyzes a novel mechanism of lipid transfer in mycobacteria. Chem Biol 21:1660\u20131669","journal-title":"Chem Biol"},{"key":"415_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s44386-025-00006-5","volume":"2","author":"KP Godinez-Macias","year":"2025","unstructured":"Godinez-Macias KP, Chen D, Wallis JL, Siegel MG, Adam A, Bopp S, Carolino K, Coulson LB, Durst G, Thathy V et al (2025) Revisiting the Plasmodium falciparum druggable genome using predicted structures and data mining. NPJ Drug Discov 2:3","journal-title":"NPJ Drug Discov"},{"key":"415_CR35","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/978-1-0716-1460-0_27","volume":"2314","author":"B Gold","year":"2021","unstructured":"Gold B, Warrier T, Nathan C (2021) A multistress model for high throughput screening against nonreplicating Mycobacterium tuberculosis. Methods Mol Biol 2314:611\u2013635","journal-title":"Methods Mol Biol"},{"key":"415_CR36","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41586-020-3004-3","volume":"589","author":"H Guo","year":"2021","unstructured":"Guo H, Courbon GM, Bueler SA, Mai J, Liu J, Rubinstein JL (2021) Structure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline. Nature 589:143\u2013147","journal-title":"Nature"},{"key":"415_CR37","doi-asserted-by":"publisher","first-page":"bbaf330","DOI":"10.1093\/bib\/bbaf330","volume":"26","author":"A Halder","year":"2025","unstructured":"Halder A, Samantaray S, Barbade S, Gupta A, Srivastava S (2025) DrugProtAI: a machine learning-driven approach for predicting protein druggability through feature engineering and robust partition-based ensemble methods. Brief Bioinform 26:bbaf330","journal-title":"Brief Bioinform"},{"key":"415_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12224-3","volume":"10","author":"EJ Hasenoehrl","year":"2019","unstructured":"Hasenoehrl EJ, Rae Sajorda D, Berney-Meyer L, Johnson S, Tufariello JM, Fuhrer T, Cook GM, Jacobs WR Jr, Berney M (2019) Derailing the aspartate pathway of Mycobacterium tuberculosis to eradicate persistent infection. Nat Commun 10:4215","journal-title":"Nat Commun"},{"key":"415_CR39","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1099\/mic.0.068585-0","volume":"159","author":"JD Hayden","year":"2013","unstructured":"Hayden JD, Brown LR, Gunawardena HP, Perkowski EF, Chen X, Braunstein M (2013) Reversible acetylation regulates acetate and propionate metabolism in Mycobacterium smegmatis. Microbiology 159:1986\u20131999","journal-title":"Microbiology"},{"key":"415_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2024.07.015","volume":"6","author":"N Heinrich","year":"2025","unstructured":"Heinrich N, de Jager V, Dreisbach J, Gross-Demel P, Schultz S, Gerbach S, Kloss F, Dawson R, Narunsky K, Matt L et al (2025) Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b\/2a trial. Lancet Microbe 6:100952","journal-title":"Lancet Microbe"},{"key":"415_CR41","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.chom.2024.04.019","volume":"32","author":"S Helaine","year":"2024","unstructured":"Helaine S, Conlon BP, Davis KM, Russell DG (2024) Host stress drives tolerance and persistence: the bane of anti-microbial therapeutics. Cell Host Microbe 32:852\u2013862","journal-title":"Cell Host Microbe"},{"key":"415_CR42","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1038\/s41591-018-0224-2","volume":"24","author":"MZ Imperial","year":"2018","unstructured":"Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C et al (2018) A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med 24:1708\u20131715","journal-title":"Nat Med"},{"key":"415_CR43","doi-asserted-by":"publisher","first-page":"e75245","DOI":"10.1371\/journal.pone.0075245","volume":"8","author":"TR Ioerger","year":"2013","unstructured":"Ioerger TR, O\u2019Malley T, Liao R, Guinn KM, Hickey MJ, Mohaideen N, Murphy KC, Boshoff HI, Mizrahi V, Rubin EJ et al (2013) Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. PLoS One 8:e75245","journal-title":"PLoS One"},{"key":"415_CR44","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1164\/rccm.202408-1632OC","volume":"211","author":"S Janssen","year":"2025","unstructured":"Janssen S, Upton C, de Jager VR, van Niekerk C, Dawson R, Hutchings J, Kim J, Choi J, Nam K, Sun E et al (2025) Telacebec, a potent agent in the fight against tuberculosis: findings from a randomized, Phase 2 clinical trial and beyond. Am J Respir Crit Care Med 211:1504\u20131512","journal-title":"Am J Respir Crit Care Med"},{"key":"415_CR45","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41586-019-1315-z","volume":"571","author":"EO Johnson","year":"2019","unstructured":"Johnson EO, LaVerriere E, Office E, Stanley M, Meyer E, Kawate T, Gomez JE, Audette RE, Bandyopadhyay N, Betancourt N et al (2019) Large-scale chemical-genetics yields new M. tuberculosis inhibitor classes. Nature 571:72\u201378","journal-title":"Nature"},{"key":"415_CR46","doi-asserted-by":"crossref","unstructured":"Keam SJ (2025) Gepotidacin: first approval. Drugs 85:1479\u20131485","DOI":"10.1007\/s40265-025-02214-9"},{"key":"415_CR47","doi-asserted-by":"publisher","first-page":"19095","DOI":"10.1073\/pnas.1315860110","volume":"110","author":"JH Kim","year":"2013","unstructured":"Kim JH, O\u2019Brien KM, Sharma R, Boshoff HI, Rehren G, Chakraborty S, Wallach JB, Monteleone M, Wilson DJ, Aldrich CC et al (2013) A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence. Proc Natl Acad Sci USA 110:19095\u201319100","journal-title":"Proc Natl Acad Sci USA"},{"key":"415_CR48","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41594-022-00918-0","volume":"30","author":"SK Kim","year":"2023","unstructured":"Kim SK, Dickinson MS, Finer-Moore J, Guan Z, Kaake RM, Echeverria I, Chen J, Pulido EH, Sali A, Krogan NJ et al (2023) Structure and dynamics of the essential endogenous mycobacterial polyketide synthase Pks13. Nat Struct Mol Biol 30:296\u2013308","journal-title":"Nat Struct Mol Biol"},{"key":"415_CR49","doi-asserted-by":"crossref","unstructured":"Krieger IV, Sukheja P, Yang B, Tang S, Selle D, Woods A, Engelhart C, Kumar P, Harbut MB, Liu D et al (2025) SuFEx-based antitubercular compound irreversibly inhibits Pks13. Nature 645:755\u2013763","DOI":"10.1038\/s41586-025-09286-3"},{"key":"415_CR50","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1021\/acsinfecdis.3c00592","volume":"10","author":"IV Krieger","year":"2024","unstructured":"Krieger IV, Yalamanchili S, Dickson P, Engelhart CA, Zimmerman MD, Wood J, Clary E, Nguyen J, Thornton N, Centrella PA et al (2024) Inhibitors of the thioesterase activity of Mycobacterium tuberculosis Pks13 discovered using DNA-encoded chemical library screening. ACS Infect Dis 10:1561\u20131575","journal-title":"ACS Infect Dis"},{"key":"415_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2021.101002","volume":"81","author":"N Kumar","year":"2021","unstructured":"Kumar N, Sharma S, Kaushal PS (2021) Protein synthesis in Mycobacterium tuberculosis as a potential target for therapeutic interventions. Mol Asp Med 81:101002","journal-title":"Mol Asp Med"},{"key":"415_CR52","doi-asserted-by":"publisher","first-page":"e00070","DOI":"10.1128\/MMBR.00070-19","volume":"84","author":"EA Lamont","year":"2020","unstructured":"Lamont EA, Dillon NA, Baughn AD (2020) The bewildering antitubercular action of pyrazinamide. Microbiol Mol Biol Rev 84:e00070\u201319","journal-title":"Microbiol Mol Biol Rev"},{"key":"415_CR53","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nsmb.1567","volume":"16","author":"N LaRonde-LeBlanc","year":"2009","unstructured":"LaRonde-LeBlanc N, Resto M, Gerratana B (2009) Regulation of active site coupling in glutamine-dependent NAD(+) synthetase. Nat Struct Mol Biol 16:421\u2013429","journal-title":"Nat Struct Mol Biol"},{"key":"415_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-10-168","volume":"10","author":"V Le Guilloux","year":"2009","unstructured":"Le Guilloux V, Schmidtke P, Tuffery P (2009) Fpocket: an open source platform for ligand pocket detection. BMC Bioinforma 10:168","journal-title":"BMC Bioinforma"},{"key":"415_CR55","doi-asserted-by":"crossref","unstructured":"Lun S, Xiao S, Zhang W, Wang S, Gunosewoyo H, Yu L-F, Bishai WR (2021) Therapeutic Potential of Coumestan Pks13 Inhibitors for Tuberculosis. Antimicrob Agents Chemother 65:e02190\u201320","DOI":"10.1128\/AAC.02190-20"},{"key":"415_CR56","doi-asserted-by":"publisher","first-page":"9819","DOI":"10.1073\/pnas.1000715107","volume":"107","author":"J Marrero","year":"2010","unstructured":"Marrero J, Rhee KY, Schnappinger D, Pethe K, Ehrt S (2010) Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection. Proc Natl Acad Sci USA 107:9819\u20139824","journal-title":"Proc Natl Acad Sci USA"},{"key":"415_CR57","doi-asserted-by":"publisher","first-page":"e466","DOI":"10.1371\/journal.pmed.0030466","volume":"3","author":"M Matsumoto","year":"2006","unstructured":"Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M (2006) OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3:e466","journal-title":"PLoS Med"},{"key":"415_CR58","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2425981122","volume":"122","author":"S Mishra","year":"2025","unstructured":"Mishra S, Singh PR, Hu X, Lopez-Quezada L, Jinich A, Jahn R, Geurts L, Shen N, DeJesus MA, Hartman T et al (2025) Candidate transmission survival genome of Mycobacterium tuberculosis. Proc Natl Acad Sci USA 122:e2425981122","journal-title":"Proc Natl Acad Sci USA"},{"key":"415_CR59","first-page":"727","volume":"131","author":"MRC TB","year":"1985","unstructured":"MRC TB (1985) Controlled clinical trial of two 6-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Tanzania\/British Medical Research Council Study. Am Rev Respir Dis 131:727\u2013731","journal-title":"Am Rev Respir Dis"},{"key":"415_CR60","doi-asserted-by":"publisher","first-page":"14114","DOI":"10.1074\/jbc.M113.463992","volume":"288","author":"S Nambi","year":"2013","unstructured":"Nambi S, Gupta K, Bhattacharyya M, Ramakrishnan P, Ravikumar V, Siddiqui N, Thomas AT, Visweswariah SS (2013) Cyclic AMP-dependent protein lysine acylation in mycobacteria regulates fatty acid and propionate metabolism. J Biol Chem 288:14114\u201314124","journal-title":"J Biol Chem"},{"key":"415_CR61","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","volume":"387","author":"BT Nyang\u2019wa","year":"2022","unstructured":"Nyang\u2019wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Solodovnikova V, Liverko I, Moodliar R, Dodd M et al (2022) A 24-week, all-oral regimen for rifampin-resistant tuberculosis. N Engl J Med 387:2331\u20132343","journal-title":"N Engl J Med"},{"key":"415_CR62","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nrd2201","volume":"6","author":"DJ Payne","year":"2007","unstructured":"Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6:29\u201340","journal-title":"Nat Rev Drug Discov"},{"key":"415_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1060","volume":"1","author":"K Pethe","year":"2010","unstructured":"Pethe K, Sequeira PC, Agarwalla S, Rhee K, Kuhen K, Phong WY, Patel V, Beer D, Walker JR, Duraiswamy J et al (2010) A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat Commun 1:57","journal-title":"Nat Commun"},{"key":"415_CR64","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/nm.3937","volume":"21","author":"B Prideaux","year":"2015","unstructured":"Prideaux B, Via LE, Zimmerman MD, Eum S, Sarathy J, O\u2019Brien P, Chen C, Kaya F, Weiner DM, Chen PY et al (2015) The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med 21:1223\u20131227","journal-title":"Nat Med"},{"key":"415_CR65","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2423114122","volume":"122","author":"M Priya","year":"2025","unstructured":"Priya M, Gupta SK, Koundal A, Kapoor S, Tiwari S, Kidwai S, Sorio de Carvalho LP, Thakur KG, Mahajan D, Sharma D et al (2025) Itaconate mechanism of action and dissimilation in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 122:e2423114122","journal-title":"Proc Natl Acad Sci USA"},{"key":"415_CR66","doi-asserted-by":"publisher","first-page":"e1004144","DOI":"10.1371\/journal.ppat.1004144","volume":"10","author":"S Puckett","year":"2014","unstructured":"Puckett S, Trujillo C, Eoh H, Marrero J, Spencer J, Jackson M, Schnappinger D, Rhee K, Ehrt S (2014) Inactivation of fructose-1,6-bisphosphate aldolase prevents optimal co-catabolism of glycolytic and gluconeogenic carbon substrates in Mycobacterium tuberculosis. PLoS Pathog 10:e1004144","journal-title":"PLoS Pathog"},{"key":"415_CR67","doi-asserted-by":"publisher","first-page":"7610","DOI":"10.1021\/bi049650w","volume":"43","author":"N Raffaelli","year":"2004","unstructured":"Raffaelli N, Finaurini L, Mazzola F, Pucci L, Sorci L, Amici A, Magni G (2004) Characterization of Mycobacterium tuberculosis NAD kinase: functional analysis of the full-length enzyme by site-directed mutagenesis. Biochemistry 43:7610\u20137617","journal-title":"Biochemistry"},{"key":"415_CR68","doi-asserted-by":"publisher","first-page":"11945","DOI":"10.1073\/pnas.0711697105","volume":"105","author":"SP Rao","year":"2008","unstructured":"Rao SP, Alonso S, Rand L, Dick T, Pethe K (2008) The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc Natl Acad Sci USA 105:11945\u201311950","journal-title":"Proc Natl Acad Sci USA"},{"key":"415_CR70","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1021\/acsptsci.3c00034","volume":"6","author":"S Rath","year":"2023","unstructured":"Rath S, Panda S, Sacchettini JC, Berthel SJ (2023) DAIKON: a data acquisition, integration, and knowledge capture web application for target-based drug discovery. ACS Pharm Transl Sci 6:1043\u20131051","journal-title":"ACS Pharm Transl Sci"},{"key":"415_CR72","doi-asserted-by":"publisher","first-page":"fuab050","DOI":"10.1093\/femsre\/fuab050","volume":"46","author":"S Remm","year":"2022","unstructured":"Remm S, Earp JC, Dick T, Dartois V, Seeger MA (2022) Critical discussion on drug efflux in Mycobacterium tuberculosis. FEMS Microbiol Rev 46:fuab050","journal-title":"FEMS Microbiol Rev"},{"key":"415_CR73","doi-asserted-by":"publisher","first-page":"e00747","DOI":"10.1128\/mBio.00747-13","volume":"5","author":"IA Rodionova","year":"2014","unstructured":"Rodionova IA, Schuster BM, Guinn KM, Sorci L, Scott DA, Li X, Kheterpal I, Shoen C, Cynamon M, Locher C et al (2014) Metabolic and bactericidal effects of targeted suppression of NadD and NadE enzymes in mycobacteria. MBio 5:e00747\u201313","journal-title":"MBio"},{"key":"415_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1441147","volume":"15","author":"J Sankar","year":"2024","unstructured":"Sankar J, Chauhan A, Singh R, Mahajan D (2024) Isoniazid-historical development, metabolism associated toxicity and a perspective on its pharmacological improvement. Front Pharm 15:1441147","journal-title":"Front Pharm"},{"key":"415_CR75","doi-asserted-by":"publisher","first-page":"e02516","DOI":"10.1128\/AAC.02516-18","volume":"63","author":"J Sarathy","year":"2019","unstructured":"Sarathy J, Blanc L, Alvarez-Cabrera N, O\u2019Brien P, Dias-Freedman I, Mina M, Zimmerman M, Kaya F, Ho Liang HP, Prideaux B et al (2019a) Fluoroquinolone efficacy against tuberculosis is driven by penetration into lesions and activity against resident bacterial populations. Antimicrob Agents Chemother 63:e02516\u2013e02518","journal-title":"Antimicrob Agents Chemother"},{"key":"415_CR76","doi-asserted-by":"publisher","first-page":"e1012595","DOI":"10.1371\/journal.ppat.1012595","volume":"20","author":"JP Sarathy","year":"2024","unstructured":"Sarathy JP (2024) Molecular and microbiological methods for the identification of nonreplicating Mycobacterium tuberculosis. PLoS Pathog 20:e1012595","journal-title":"PLoS Pathog"},{"key":"415_CR77","doi-asserted-by":"publisher","first-page":"e00159","DOI":"10.1128\/CMR.00159-19","volume":"33","author":"JP Sarathy","year":"2020","unstructured":"Sarathy JP, Dartois V (2020) Caseum: a Niche for Mycobacterium tuberculosis drug-tolerant persisters. Clin Microbiol Rev 33:e00159\u201319","journal-title":"Clin Microbiol Rev"},{"key":"415_CR78","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3390\/antibiotics8040261","volume":"8","author":"JP Sarathy","year":"2019","unstructured":"Sarathy JP, Gruber G, Dick T (2019b) Re-understanding the Mechanisms of action of the anti-mycobacterial drug bedaquiline. Antibiotics 8:261","journal-title":"Antibiotics"},{"key":"415_CR79","doi-asserted-by":"publisher","first-page":"e0059823","DOI":"10.1128\/mbio.00598-23","volume":"14","author":"JP Sarathy","year":"2023","unstructured":"Sarathy JP, Xie M, Jones RM, Chang A, Osiecki P, Weiner D, Tsao WS, Dougher M, Blanc L, Fotouhi N et al (2023) A novel tool to identify bactericidal compounds against vulnerable targets in drug-tolerant M. tuberculosis found in caseum. mBio 14:e0059823","journal-title":"mBio"},{"key":"415_CR80","doi-asserted-by":"publisher","first-page":"12989","DOI":"10.1073\/pnas.2134250100","volume":"100","author":"CM Sassetti","year":"2003","unstructured":"Sassetti CM, Rubin EJ (2003) Genetic requirements for mycobacterial survival during infection. Proc Natl Acad Sci USA 100:12989\u201312994","journal-title":"Proc Natl Acad Sci USA"},{"key":"415_CR81","doi-asserted-by":"publisher","first-page":"e0034023","DOI":"10.1128\/mbio.00340-23","volume":"14","author":"R Sharma","year":"2023","unstructured":"Sharma R, Hartman TE, Beites T, Kim JH, Eoh H, Engelhart CA, Zhu L, Wilson DJ, Aldrich CC, Ehrt S et al (2023) Metabolically distinct roles of NAD synthetase and NAD kinase define the essentiality of NAD and NADP in Mycobacterium tuberculosis. mBio 14:e0034023","journal-title":"mBio"},{"key":"415_CR82","doi-asserted-by":"publisher","first-page":"18194","DOI":"10.1021\/ja204036t","volume":"133","author":"C Shi","year":"2011","unstructured":"Shi C, Geders TW, Park SW, Wilson DJ, Boshoff HI, Abayomi O, Barry 3rdCE, Schnappinger D, Finzel BC, Aldrich CC (2011) Mechanism-based inactivation by aromatization of the transaminase BioA involved in biotin biosynthesis in Mycobacterium tuberculosis. J Am Chem Soc 133:18194\u201318201","journal-title":"J Am Chem Soc"},{"key":"415_CR83","doi-asserted-by":"crossref","unstructured":"Showalter HD (2020) Recent progress in the discovery and development of 2-nitroimidazooxazines and 6-nitroimidazooxazoles to treat tuberculosis and neglected tropical diseases. Molecules 25:4137","DOI":"10.3390\/molecules25184137"},{"key":"415_CR84","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1128\/CMR.00030-10","volume":"24","author":"LL Silver","year":"2011","unstructured":"Silver LL (2011) Challenges of antibacterial discovery. Clin Microbiol Rev 24:71\u2013109","journal-title":"Clin Microbiol Rev"},{"key":"415_CR85","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41570-023-00472-3","volume":"7","author":"V Singh","year":"2023","unstructured":"Singh V, Dziwornu GA, Chibale K (2023) The implication of Mycobacterium tuberculosis-mediated metabolism of targeted xenobiotics. Nat Rev Chem 7:340\u2013354","journal-title":"Nat Rev Chem"},{"key":"415_CR86","doi-asserted-by":"publisher","first-page":"e74419","DOI":"10.7554\/eLife.74419","volume":"11","author":"CM Smith","year":"2022","unstructured":"Smith CM, Baker RE, Proulx MK, Mishra BB, Long JE, Park SW, Lee HN, Kiritsy MC, Bellerose MM, Olive AJ et al (2022) Host-pathogen genetic interactions underlie tuberculosis susceptibility in genetically diverse mice. Elife 11:e74419","journal-title":"Elife"},{"key":"415_CR87","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/nm0597-567","volume":"3","author":"A Telenti","year":"1997","unstructured":"Telenti A, Philipp WJ, Sreevatsan S, Bernasconi C, Stockbauer KE, Wieles B, Musser JM, Jacobs WR Jr (1997) The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat Med 3:567\u2013570","journal-title":"Nat Med"},{"key":"415_CR88","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1371\/journal.pbio.0050263","volume":"5","author":"W Tempel","year":"2007","unstructured":"Tempel W, Rabeh WM, Bogan KL, Belenky P, Wojcik M, Seidle HF, Nedyalkova L, Yang T, Sauve AA, Park HW et al (2007) Nicotinamide riboside kinase structures reveal new pathways to NAD+. PLoS Biol 5:e263","journal-title":"PLoS Biol"},{"key":"415_CR89","doi-asserted-by":"publisher","first-page":"e1004679","DOI":"10.1371\/journal.ppat.1004679","volume":"11","author":"BC VanderVen","year":"2015","unstructured":"VanderVen BC, Fahey RJ, Lee W, Liu Y, Abramovitch RB, Memmott C, Crowe AM, Eltis LD, Perola E, Deininger DD et al (2015) Novel inhibitors of cholesterol degradation in Mycobacterium tuberculosis reveal how the bacterium\u2019s metabolism is constrained by the intracellular environment. PLoS Pathog 11:e1004679","journal-title":"PLoS Pathog"},{"key":"415_CR90","doi-asserted-by":"publisher","first-page":"22315","DOI":"10.1074\/jbc.M116.744532","volume":"291","author":"O Vergnolle","year":"2016","unstructured":"Vergnolle O, Xu H, Tufariello JM, Favrot L, Malek AA, Jacobs WR Jr, Blanchard JS (2016) Post-translational acetylation of MbtA modulates mycobacterial siderophore biosynthesis. J Biol Chem 291:22315\u201322326","journal-title":"J Biol Chem"},{"key":"415_CR91","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1365-2958.2010.07099.x","volume":"76","author":"C Vilcheze","year":"2010","unstructured":"Vilcheze C, Weinrick B, Wong KW, Chen B, Jacobs WR Jr (2010) NAD+ auxotrophy is bacteriocidal for the tubercle bacilli. Mol Microbiol 76:365\u2013377","journal-title":"Mol Microbiol"},{"key":"415_CR92","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1016\/j.bmcl.2017.08.012","volume":"27","author":"X Wang","year":"2017","unstructured":"Wang X, Ahn YM, Lentscher AG, Lister JS, Brothers RC, Kneen MM, Gerratana B, Boshoff HI, Dowd CS (2017) Design, synthesis, and evaluation of substituted nicotinamide adenine dinucleotide (NAD(+)) synthetase inhibitors as potential antitubercular agents. Bioorg Med Chem Lett 27:4426\u20134430","journal-title":"Bioorg Med Chem Lett"},{"key":"415_CR93","doi-asserted-by":"crossref","unstructured":"Warner DF, Barczak AK, Gutierrez MG, Mizrahi V (2025) Mycobacterium tuberculosis biology, pathogenicity and interaction with the host. Nat Rev Microbiol 23:788\u2013804","DOI":"10.1038\/s41579-025-01201-x"},{"key":"415_CR94","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1128\/iai.64.6.2062-2069.1996","volume":"64","author":"LG Wayne","year":"1996","unstructured":"Wayne LG, Hayes LG (1996) An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 64:2062\u20132069","journal-title":"Infect Immun"},{"issue":"Suppl 3","key":"415_CR95","doi-asserted-by":"publisher","first-page":"S407","DOI":"10.1093\/clinids\/5.Supplement_3.S407","volume":"5","author":"W Wehrli","year":"1983","unstructured":"Wehrli W (1983) Rifampin: mechanisms of action and resistance. Rev Infect Dis 5(Suppl 3):S407\u2013S411","journal-title":"Rev Infect Dis"},{"key":"415_CR96","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1073\/pnas.1018301108","volume":"108","author":"JR Wei","year":"2011","unstructured":"Wei JR, Krishnamoorthy V, Murphy K, Kim JH, Schnappinger D, Alber T, Sassetti CM, Rhee KY, Rubin EJ (2011) Depletion of antibiotic targets has widely varying effects on growth. Proc Natl Acad Sci USA 108:4176\u20134181","journal-title":"Proc Natl Acad Sci USA"},{"key":"415_CR97","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1021\/acsinfecdis.7b00255","volume":"4","author":"S Wellington","year":"2018","unstructured":"Wellington S, Hung DT (2018) The expanding diversity of Mycobacterium tuberculosis drug targets. ACS Infect Dis 4:696\u2013714","journal-title":"ACS Infect Dis"},{"key":"415_CR98","unstructured":"W.H.O. (2022) W.H.O. Consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant treatment, 2022 update. World Health Organization, Geneva"},{"key":"415_CR99","unstructured":"W.H.O. (2025) Global tuberculosis report. World Health Organization"},{"key":"415_CR100","doi-asserted-by":"publisher","first-page":"e1009862","DOI":"10.1371\/journal.ppat.1009862","volume":"18","author":"KM Wilburn","year":"2022","unstructured":"Wilburn KM, Montague CR, Qin B, Woods AK, Love MS, McNamara CW, Schultz PG, Southard TL, Huang L, Petrassi HM et al (2022) Pharmacological and genetic activation of cAMP synthesis disrupts cholesterol utilization in Mycobacterium tuberculosis. PLoS Pathog 18:e1009862","journal-title":"PLoS Pathog"},{"key":"415_CR101","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1021\/acs.jmedchem.1c01586","volume":"65","author":"C Wilson","year":"2022","unstructured":"Wilson C, Ray P, Zuccotto F, Hernandez J, Aggarwal A, Mackenzie C, Caldwell N, Taylor M, Huggett M, Mathieson M et al (2022) Optimization of TAM16, a benzofuran that inhibits the thioesterase activity of Pks13; evaluation toward a preclinical candidate for a novel antituberculosis clinical target. J Med Chem 65:409\u2013423","journal-title":"J Med Chem"},{"key":"415_CR102","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nchembio.1277","volume":"9","author":"R Wilson","year":"2013","unstructured":"Wilson R, Kumar P, Parashar V, Vilcheze C, Veyron-Churlet R, Freundlich JS, Barnes SW, Walker JR, Szymonifka MJ, Marchiano E et al (2013) Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis. Nat Chem Biol 9:499\u2013506","journal-title":"Nat Chem Biol"},{"key":"415_CR103","doi-asserted-by":"publisher","first-page":"e1002264","DOI":"10.1371\/journal.ppat.1002264","volume":"7","author":"S Woong Park","year":"2011","unstructured":"Woong Park S, Klotzsche M, Wilson DJ, Boshoff HI, Eoh H, Manjunatha U, Blumenthal A, Rhee K, Barry 3rdCE, Aldrich CC et al (2011) Evaluating the sensitivity of Mycobacterium tuberculosis to biotin deprivation using regulated gene expression. PLoS Pathog 7:e1002264","journal-title":"PLoS Pathog"},{"key":"415_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115702","volume":"259","author":"F Xia","year":"2023","unstructured":"Xia F, Zhang H, Yang H, Zheng M, Min W, Sun C, Yuan K, Yang P (2023) Targeting polyketide synthase 13 for the treatment of tuberculosis. Eur J Med Chem 259:115702","journal-title":"Eur J Med Chem"},{"key":"415_CR105","doi-asserted-by":"publisher","first-page":"5883","DOI":"10.1021\/bi200156t","volume":"50","author":"H Xu","year":"2011","unstructured":"Xu H, Hegde SS, Blanchard JS (2011) Reversible acetylation and inactivation of Mycobacterium tuberculosis acetyl-CoA synthetase is dependent on cAMP. Biochemistry 50:5883\u20135892","journal-title":"Biochemistry"},{"key":"415_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/s41426-018-0032-2","volume":"7","author":"H Yang","year":"2018","unstructured":"Yang H, Sha W, Liu Z, Tang T, Liu H, Qin L, Cui Z, Chen J, Liu F, Zheng R et al (2018) Lysine acetylation of DosR regulates the hypoxia response of Mycobacterium tuberculosis. Emerg Microbes Infect 7:34","journal-title":"Emerg Microbes Infect"},{"key":"415_CR107","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1074\/mcp.M114.045922","volume":"14","author":"M Yang","year":"2015","unstructured":"Yang M, Wang Y, Chen Y, Cheng Z, Gu J, Deng J, Bi L, Chen C, Mo R, Wang X et al (2015) Succinylome analysis reveals the involvement of lysine succinylation in metabolism in pathogenic Mycobacterium tuberculosis. Mol Cell Proteom 14:796\u2013811","journal-title":"Mol Cell Proteom"},{"key":"415_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102332","volume":"66","author":"SMA Zaidi","year":"2023","unstructured":"Zaidi SMA, Coussens AK, Seddon JA, Kredo T, Warner D, Houben R, Esmail H (2023) Beyond latent and active tuberculosis: a scoping review of conceptual frameworks. EClinicalMedicine 66:102332","journal-title":"EClinicalMedicine"},{"key":"415_CR109","doi-asserted-by":"publisher","first-page":"13240","DOI":"10.1021\/acs.jmedchem.2c01064","volume":"65","author":"W Zhang","year":"2022","unstructured":"Zhang W, Lun S, Wang SS, Cai YP, Yang F, Tang J, Bishai WR, Yu LF (2022) Structure-based optimization of coumestan derivatives as polyketide synthase 13-thioesterase(Pks13-TE) inhibitors with improved hERG profiles for Mycobacterium tuberculosis treatment. J Med Chem 65:13240\u201313252","journal-title":"J Med Chem"},{"key":"415_CR110","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S1473-3099(13)70328-1","volume":"14","author":"AI Zumla","year":"2014","unstructured":"Zumla AI, Gillespie SH, Hoelscher M, Philips PP, Cole ST, Abubakar I, McHugh TD, Schito M, Maeurer M, Nunn AJ (2014) New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis 14:327\u2013340","journal-title":"Lancet Infect Dis"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00415-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-026-00415-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00415-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:45:00Z","timestamp":1779065100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-026-00415-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":108,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,15]]}},"alternative-id":["415"],"URL":"https:\/\/doi.org\/10.1038\/s44321-026-00415-7","relation":{},"ISSN":["1757-4684"],"issn-type":[{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests. Dr. Valerie Mizrahi is a member of the EMM Editorial Board. This has no bearing on the editorial consideration of this article for publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}]}}